← Back to Home

B7-H3 antibody drug delays progression in recurrent osteosarcoma, while phase 3 trial also highlights toxicity burden

Ris-Rez extended median progression-free survival from 1.4 to 5.5 months in patients with osteosarcoma who had received multiple lines of treatment; however, more than 90% experienced grade 3 or higher treatment-related adverse events, and whether it prolongs life remains uncertain.

By SURL BioNews

For patients with repeatedly recurrent osteosarcoma who have received multiple lines of treatment, gaining time without disease progression is an important goal amid limited options. Risvutatug rezetecan (Ris-Rez, development code HS-20093), an antibody-drug conjugate developed by Hansoh Pharma, significantly delayed disease progression in a phase 3 trial in China, providing new treatment evidence for these patients. However, frequent hematologic toxicity and the need for dose reductions also make the treatment burden a key consideration alongside efficacy.

The ARTEMIS-011 study presented its primary results at the 2026 European Society for Medical Oncology (ESMO) Congress. It enrolled 122 patients aged 12 years and older across 24 centers in China, all of whom had received at least two lines of systemic therapy. The study randomly assigned patients to Ris-Rez or chemotherapy with gemcitabine plus docetaxel; Ris-Rez was administered at 12 milligrams per kilogram of body weight once every three weeks. Although the trial had an open-label design, the primary efficacy endpoint was assessed by blinded independent central review.

As of June 17, 2026, after a median follow-up of 7.1 months, median progression-free survival was 5.5 months in the Ris-Rez group and 1.4 months in the chemotherapy group. The hazard ratio for disease progression or death was 0.33 (95% confidence interval, 0.20 to 0.55; p<0.0001), corresponding to a 67% relative risk reduction. The proportions of patients who remained free of progression at four months were 65% and 33%, respectively. These results support the drug’s ability to delay disease progression, but progression-free survival is not equivalent to overall survival.

Ris-Rez uses an antibody to recognize the B7-H3 protein and carries a topoisomerase I inhibitor, with the aim of delivering a cytotoxic drug to tumor cells. However, this delivery method still comes with substantial side effects: grade 3 or higher treatment-related adverse events occurred in 93% of patients, compared with 83% in the chemotherapy group. These included decreased neutrophil counts in 79% versus 43% and anemia in 63% versus 29%.

The treatment burden was also reflected in dose adjustments. According to conference data compiled by OncLive, serious treatment-related adverse events occurred in 64% of the Ris-Rez group and 29% of the chemotherapy group. Dose reductions due to adverse events occurred in 71% and 26%, respectively, and neither group had any treatment-related deaths. Patients in the Ris-Rez group received treatment for longer, which must be considered when interpreting cumulative adverse event rates. Nevertheless, the high rate of dose reductions makes dose selection and toxicity management important issues for further development.

Whether patients live longer as a result remains uncertain. Overall survival data were still immature, with only 10 deaths recorded in each group. The hazard ratio was 0.51, but the 95% confidence interval ranged from 0.21 to 1.23, which was insufficient to establish a survival advantage. Another 17 patients in the chemotherapy group switched to Ris-Rez after disease progression, further complicating the interpretation of subsequent survival analyses. All participants were from China, and more data are needed to determine whether the results can be extended to other healthcare settings and patient populations.

There has been a more recent update on regulatory progress. On October 26, GSK was still stating that the results would support a filing in China. The following day, Hansoh announced that China’s National Medical Products Administration had accepted the biologics license application for the osteosarcoma indication on September 24 and granted priority review; this does not mean approval has been granted. GSK is also conducting a global early-stage clinical study covering osteosarcoma and soft tissue sarcoma to further clarify the benefits, risks, and appropriate dose. For this new therapy, delayed progression is now supported by randomized trial evidence. The next step is to establish whether that additional time can translate into benefits that patients can tolerate and that last longer.

References

  1. GSK
  2. Hansoh Pharmaceutical
  3. OncLive
  4. CancerNetwork